133 related articles for article (PubMed ID: 11874406)
1. Fracture risk is increased in patients with GH deficiency or untreated prolactinomas--a case-control study.
Vestergaard P; Jørgensen JO; Hagen C; Hoeck HC; Laurberg P; Rejnmark L; Brixen K; Weeke J; Andersen M; Conceicao FL; Nielsen TL; Mosekilde L
Clin Endocrinol (Oxf); 2002 Feb; 56(2):159-67. PubMed ID: 11874406
[TBL] [Abstract][Full Text] [Related]
2. Fractures in pituitary adenoma patients from the Dutch National Registry of Growth Hormone Treatment in Adults.
van Varsseveld NC; van Bunderen CC; Franken AA; Koppeschaar HP; van der Lely AJ; Drent ML
Pituitary; 2016 Aug; 19(4):381-90. PubMed ID: 27048484
[TBL] [Abstract][Full Text] [Related]
3. Divergence between growth hormone responses to insulin-induced hypoglycaemia and growth hormone-releasing hormone in patients with non-functioning pituitary macroadenomas and hyperprolactinaemia.
Beentjes JA; Tjeerdsma G; Sluiter WJ; Dullaart RP
Clin Endocrinol (Oxf); 1996 Oct; 45(4):391-8. PubMed ID: 8959076
[TBL] [Abstract][Full Text] [Related]
4. Prevalence of autoimmune disease in patients with prolactinomas and non-functioning pituitary adenomas.
Larouche V; Correa JA; Cassidy P; Beauregard C; Garfield N; Rivera J
Pituitary; 2016 Apr; 19(2):202-9. PubMed ID: 26700946
[TBL] [Abstract][Full Text] [Related]
5. Diagnosis, treatment, and outcome of pituitary tumors and other abnormal intrasellar masses. Retrospective analysis of 353 patients.
Gsponer J; De Tribolet N; Déruaz JP; Janzer R; Uské A; Mirimanoff RO; Reymond MJ; Rey F; Temler E; Gaillard RC; Gomez F
Medicine (Baltimore); 1999 Jul; 78(4):236-69. PubMed ID: 10424206
[TBL] [Abstract][Full Text] [Related]
6. The incidence rate of pituitary adenomas in western Sweden for the period 2001-2011.
Tjörnstrand A; Gunnarsson K; Evert M; Holmberg E; Ragnarsson O; Rosén T; Filipsson Nyström H
Eur J Endocrinol; 2014 Oct; 171(4):519-26. PubMed ID: 25084775
[TBL] [Abstract][Full Text] [Related]
7. Comorbidity and cardiovascular risk factors in adult GH deficiency following treatment for Cushing's disease or non-functioning pituitary adenomas during childhood.
Ragnarsson O; Höybye C; Jönsson PJ; Feldt-Rasmussen U; Johannsson G; Biller BM; Koltowska-Häggström M
Eur J Endocrinol; 2012 Apr; 166(4):593-600. PubMed ID: 22258111
[TBL] [Abstract][Full Text] [Related]
8. [Long-term effects of 7-year growth hormone substitution on bone metabolism, bone density, and bone quality in growth hormone-deficient adults].
Wilhelm B; Kann PH
Med Klin (Munich); 2004 Oct; 99(10):569-77. PubMed ID: 15490072
[TBL] [Abstract][Full Text] [Related]
9. Acquired prolactin deficiency (APD) after treatment for Cushing's disease is a reliable marker of irreversible severe GHD but does not reflect disease status.
Mukherjee A; Murray RD; Teasdale GM; Shalet SM
Clin Endocrinol (Oxf); 2004 Apr; 60(4):476-83. PubMed ID: 15049963
[TBL] [Abstract][Full Text] [Related]
10. Increased incidence of neoplasia in patients with pituitary adenomas. The Pituitary Study Group.
Popovic V; Damjanovic S; Micic D; Nesovic M; Djurovic M; Petakov M; Obradovic S; Zoric S; Simic M; Penezic Z; Marinkovic J
Clin Endocrinol (Oxf); 1998 Oct; 49(4):441-5. PubMed ID: 9876340
[TBL] [Abstract][Full Text] [Related]
11. Elderly people with hypothalamic-pituitary disease and untreated GH deficiency: clinical outcome, body composition, lipid profiles and quality of life after 2 years compared to controls.
Li Voon Chong JS; Groves T; Foy P; Wallymahmed ME; MacFarlane IA
Clin Endocrinol (Oxf); 2002 Feb; 56(2):175-81. PubMed ID: 11874408
[TBL] [Abstract][Full Text] [Related]
12. Pituitary adenomas in childhood, adolescence and young adulthood: presentation, management, endocrine and metabolic outcomes.
Steele CA; MacFarlane IA; Blair J; Cuthbertson DJ; Didi M; Mallucci C; Javadpour M; Daousi C
Eur J Endocrinol; 2010 Oct; 163(4):515-22. PubMed ID: 20685833
[TBL] [Abstract][Full Text] [Related]
13. Age-related and gender-related occurrence of pituitary adenomas.
Mindermann T; Wilson CB
Clin Endocrinol (Oxf); 1994 Sep; 41(3):359-64. PubMed ID: 7893282
[TBL] [Abstract][Full Text] [Related]
14. Ghrelin and growth hormone (GH) secretagogue receptor (GHSR) mRNA expression in human pituitary adenomas.
Kim K; Arai K; Sanno N; Osamura RY; Teramoto A; Shibasaki T
Clin Endocrinol (Oxf); 2001 Jun; 54(6):759-68. PubMed ID: 11422110
[TBL] [Abstract][Full Text] [Related]
15. Growth hormone and prolactin responses to corticotrophin-releasing-hormone in patients with Cushing's disease: a paracrine action of the adenomatous corticotrophic cells?
Loli P; Boccardi E; Branca V; Bramerio M; Barberis M; Losa M; Terreni MT; Lodrini S; Pollo B; Vignati F
Clin Endocrinol (Oxf); 1998 Oct; 49(4):433-9. PubMed ID: 9876339
[TBL] [Abstract][Full Text] [Related]
16. Metabolic, cardiovascular, and cerebrovascular outcomes in growth hormone-deficient subjects with previous cushing's disease or non-functioning pituitary adenoma.
Webb SM; Mo D; Lamberts SW; Melmed S; Cavagnini F; Pecori Giraldi F; Strasburger CJ; Zimmermann AG; Woodmansee WW;
J Clin Endocrinol Metab; 2010 Feb; 95(2):630-8. PubMed ID: 20022992
[TBL] [Abstract][Full Text] [Related]
17. Increased risk of osteoporotic fractures in patients with Cushing's syndrome.
Vestergaard P; Lindholm J; Jørgensen JO; Hagen C; Hoeck HC; Laurberg P; Rejnmark L; Brixen K; Kristensen LØ; Feldt-Rasmussen U; Mosekilde L
Eur J Endocrinol; 2002 Jan; 146(1):51-6. PubMed ID: 11751067
[TBL] [Abstract][Full Text] [Related]
18. The risk of osteopenia in premenopausal women with various sellar tumors.
Zhao Y; Gan X; Luo P; He Q; Guo Q; Zhang L; Zhang X; Zhang X; Fei Z
Gynecol Endocrinol; 2012 Dec; 28(12):945-8. PubMed ID: 22553947
[TBL] [Abstract][Full Text] [Related]
19. Dopamine D2 receptor imaging in pituitary adenomas using iodine-123-epidepride and SPECT.
Pirker W; Riedl M; Luger A; Czech T; Rössler K; Asenbaum S; Angelberger P; Kornhuber J; Deecke L; Podreka I; Brücke T
J Nucl Med; 1996 Dec; 37(12):1931-7. PubMed ID: 8970508
[TBL] [Abstract][Full Text] [Related]
20. Investigating the role of cortisol and growth hormone in fatty liver development: fatty liver index in patients with pituitary adenomas.
Auer MK; Stalla GK; Stieg MR
Pituitary; 2016 Oct; 19(5):461-71. PubMed ID: 27194386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
